Fig. 2From: Effect of sofosbuvir-based DAAs on changes in lower-density lipoprotein in HCV patients: a systematic review and meta-analysisForest plots for changes in low-density lipoprotein from baseline to week 4 (A), to the end of treatment (B), to post-treatment week 12 (C), and to post-treatment week 24 (D) between patients treated with sofosbuvir-based and those with non-sofosbuvir direct-acting antiviralsBack to article page